19 results
8-K
CYTK
Cytokinetics Inc
5 Apr 24
Other Events
7:30am
48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), the open label extension … taking place from April 6, 2024 –April 8, 2024 in Atlanta, GA.
FOREST-HCM enrolled 213 patients with obstructive HCM from May 28, 2021 through
8-K
EX-99.1
CYTK
Cytokinetics Inc
27 Feb 24
Cytokinetics Reports Fourth Quarter 2023 Financial Results
4:05pm
data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM) in January at CMR 2024 demonstrating
8-K
EX-99.1
CYTK
Cytokinetics Inc
2 Nov 23
Cytokinetics Reports Third Quarter 2023 Financial Results
4:05pm
of Aficamten in Obstructive HCM,
in Late December
Long-Term Data from FOREST-HCM,
the Open-Label Extension Study of Aficamten,
Show Sustained Improvements … standard of care,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In addition, we recently shared longer-term data from FOREST
8-K
EX-99.1
hcg8c8 hcr
19 Oct 23
Regulation FD Disclosure
7:32am
8-K
EX-99.1
nb0wynyiw qeroz3ql
4 May 23
Cytokinetics Reports First Quarter 2023 Financial Results
4:03pm
8-K
EX-99.1
gwc6qj0
3 Nov 22
Cytokinetics Reports Third Quarter 2022 Financial Results
4:06pm
- Prev
- 1
- Next